Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Fresenius in patent dispute over hypocalcemia treatment
Americas
Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.   7 December 2021
BGI hit with $8m damages bill in patent dispute with Illumina
Americas
Illumina has secured an $8 million damages verdict against China-based BGI Genomics, and its US subsidiary, MGI, in a dispute involving gene-sequencing patents.   2 December 2021
Moderna exposed after losing COVID-19 vaccine patent decision
Americas
Moderna has failed to reverse an unfavourable ruling related to its COVID-19 vaccine technology, after the US Court of Appeals for the Federal Circuit upheld the validity of a patent owned by Arbutus Biopharma.   2 December 2021
Americas
A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.   30 November 2021
Americas
Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.   25 November 2021
Americas
BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.   23 November 2021
Generics
Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.   23 November 2021
Americas
The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.   18 November 2021
Americas
Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.   16 November 2021
article
The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.   11 November 2021

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.